Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, with highly variable clinical outcomes ranging from spontaneous remission to progression to chronic kidney disease. Initial clinical response is a reliable predictor of long-term course. We evaluated longitudinal changes in proteinuria, serum albumin, renal function, and treatment response over an 18-month follow-up period in patients with biopsy-proven MN enrolled in a pan-India glomerulonephritis (GN) registry.
I-TANGIBLE is an ICMR-funded collaborative registry of adult patients with biopsy-proven GN representing 13 centres in India. A total of 915 MN cases were recruited between June 2022 and June 2025. 18 months follow-up data were available for 303. Clinical and biochemical parameters — proteinuria, serum albumin, serum creatinine, and estimated glomerular filtration rate (eGFR) — were assessed at baseline, 3, 6, 9, 12, and 18 months. Treatment response was categorized as complete, partial, or no remission based on KDIGO criteria.
The cohort included 182 males and 121 females, with a mean age of 45 ±13 years. At baseline, the median proteinuria was 7.07 g/day (4.3,9.9) mean serum albumin 2.6 ±0.64 g/dL, and median serum creatinine 0.9 (0.7,1.9) mg/dL. A total of 120 (39.7 %) patients were treated with rituximab, 151(49.83 %) received cyclical cyclophosphamide and corticosteroid-based therapy and 32(10.2%) patients did not receive any immunosuppression. At 12 months, proteinuria, serum albumin, and serum creatinine improved to 1.095 (0.319,3.57) g/day, 3.75±0.767 g/dL, and 0.9 (0.73,1.2) mg/dL, respectively. Over 18 months, 100 (33%) achieved complete clinical remission, 120 (39.6%) partial remission, 37 (12.2%) relapsed, 44 (14.5%) had no response, and out of resistance cases 2 (less than 1 %) progressed to end-stage kidney disease (ESKD). PLA2R antibodies were positive in 219 (72.3%) patients (median titre 176.3 [72.2,445.8] RU). Remission rates were comparable for rituximab and cyclical cyclophosphamide and corticosteroid regimen (p=0.05)
In this multicentric cohort of patients with membranous nephropathy and nephrotic syndrome at high risk of progression, three-fourths of patients achieved and maintained clinical remission. Both CYC/CS and rituximab therapies were comparably effective in inducing remission. Continued follow-up will help determine long-term renal outcomes and CKD progression.
